
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd is witnessing a significant increase in equipment utilization, having risen by over 50% since the establishment of recent investments, which supports a positive revenue outlook. Additionally, the company is poised for accelerated revenue growth through strategic investments and a shift towards pay-per-use models, expanding potential markets beyond traditional psychiatry into neurology. The improved clinic infrastructure and complementary offerings alongside established pharmacotherapies further enhance BrainsWay's market positioning and growth potential in the noninvasive neurostimulation sector.
Bears say
The fundamental reasons for a negative outlook on BrainsWay's stock include the risk of slower-than-expected adoption of Deep TMS systems, which could hinder revenue growth. Additionally, the company's challenges in expanding reimbursement and market access may further limit its financial performance and profitability. Moreover, the inability to advance into other indications and potential long-term dilution risks raise concerns about the sustainability of its market position and investor confidence.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares